Verdiva Bio

Verdiva Bio Completes Enrollment for Phase 2b EVOLVE-2 Study of VRB-101

Verdiva Bio Advances Obesity Therapy with Once-Weekly Oral GLP-1 Peptide Analog Is the pharmaceutical industry on the brink of a breakthrough in obesity treatment? Verdiva Bio Limited a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic…

Read MoreVerdiva Bio Completes Enrollment for Phase 2b EVOLVE-2 Study of VRB-101
Alluvium

Alluvium Unveils AI-Powered Platform to Transform Health System Access and Capacity

Rebranding and New Platform Reflect Alluvium’s Commitment to Unified Data Management How can health systems navigate the complex challenges of capacity management and revenue optimization? Alluvium, formerly known as BlockIt, is addressing this critical issue with the launch of its…

Read MoreAlluvium Unveils AI-Powered Platform to Transform Health System Access and Capacity
Alcanza Clinical

Alcanza Clinical Research Wins 2025 HCPEA Impact Award for Inclusive Research

Alcanza Clinical Research Recognized for Advancing Community-Based Clinical Trials How can healthcare organizations ensure that clinical research truly reflects the communities it serves? The Healthcare Private Equity Association (HCPEA) has recognized Alcanza Clinical Research (Alcanza) with its 2025 HCPEA Impact…

Read MoreAlcanza Clinical Research Wins 2025 HCPEA Impact Award for Inclusive Research
IntraBio Inc.

IntraBio Inc. Secures Orphan Medicinal Product Designation for CACNA1A Disorders

Positive Opinion Paves Way for Phase III Trial of Acetylleucine in Rare Neurological Conditions Why are rare neurological disorders often overlooked in drug development? IntraBio Inc., an Austin, Texas-based global biopharmaceutical company, is addressing this gap by advancing a potential…

Read MoreIntraBio Inc. Secures Orphan Medicinal Product Designation for CACNA1A Disorders